Lyell Immunopharma, INC Form 4 insider transactions

Lyell Immunopharma's VP, Corporate Controller, Veronica Sanchez Bulis, reported the acquisition of 8,750 restricted stock units and the sale of 254 shares to cover tax obligations.

Lyell Immunopharma's Chief Medical Officer, David Shook, was granted 50,000 stock options and reported beneficial ownership of 21,900 common shares.

Lyell Immunopharma's VP, Corporate Controller, Veronica Sanchez Bulis, reported selling 2,072 shares of common stock in two separate transactions in late 2025.

Lyell Immunopharma's President and CEO, Lynn Seely, sold 412 shares of common stock at $16.11 per share to cover tax withholding obligations.

Lyell Immunopharma's VP, Corporate Controller, Veronica Sanchez Bulis, sold 239 shares of common stock to cover tax withholding obligations from vested restricted stock units.

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold 138 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, sold 95 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, was granted 75,000 stock options with an exercise price of $17.23, vesting over approximately 3.5 years.

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, acquired 68,000 stock options at an exercise price of $17.23, effective October 27, 2025.

Lyell Immunopharma's President and CEO, Lynn Seely, was granted 175,000 stock options and holds 67,571 shares of common stock.

Lyell Immunopharma's President and CEO, Lynn Seely, acquired 40,000 shares of common stock due to performance criteria achievement and sold 7,257 shares to cover tax withholding obligations.

Lyell Immunopharma's Chief Operating Officer, Stephen Hill, reported the acquisition of 8,000 shares from RSU vesting and the sale of 1,004 shares for tax obligations.

Lyell Immunopharma's CFO, Charles W. Newton, acquired 4,000 shares through RSU vesting and sold 1,453 shares to cover tax obligations.

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, reported the acquisition of 8,000 shares from vested performance-based restricted stock units and the sale of 1,453 shares for tax withholding.

Lyell Immunopharma's President and CEO, Lynn Seely, sold shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, sold shares to cover tax withholding obligations from vested restricted stock units.

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold shares to cover tax withholding obligations from vested restricted stock units.

Lyell Immunopharma's Chief Financial Officer, Charles W. Newton, sold shares to cover tax withholding obligations from vested restricted stock units.

ARCH Venture Partners IX, along with its affiliated funds and managing directors, has reported a combined beneficial ownership of 1,820,634 shares of Lyell Immunopharma common stock following a 1-for-20 reverse stock split.

Lyell Immunopharma, Inc. Director Mark Bachleda was granted 13,000 stock options with an exercise price of $12.47, vesting monthly over three years.

Lyell Immunopharma, Inc.'s General Counsel, Mark A. Meltz, was granted 100,000 stock options with an exercise price of $12.47, vesting over four years.

Lyell Immunopharma's Chief Medical Officer, David Shook, was granted 21,900 restricted stock units and options to purchase 43,750 shares of common stock, effective June 9, 2025.

Director Richard Klausner reports acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Director William J.L. Rieflin acquired 130,000 stock options in Lyell Immunopharma, Inc. on May 15, 2025.

Director Cathy Friedman reports acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Director Otis W. Brawley acquired 130,000 stock options in Lyell Immunopharma, Inc. on May 15, 2025.

Director Elizabeth Nabel acquired 130,000 stock options in Lyell Immunopharma, Inc. on May 15, 2025, vesting dependent on continued service.

Director Sumant Ramachandra reports acquisition of Lyell Immunopharma shares held in trust and stock options.

Director Brawley Otis W reports acquiring 35,640 shares of Lyell Immunopharma, Inc. common stock at $0.56 per share on March 31, 2025.

Director Sumant Ramachandra purchased 200,000 shares of Lyell Immunopharma at an average price of $0.5761 on March 21, 2025.